Yong Dai, Frontera Therapeutics CEO
Scoop: Little-known OrbiMed-backed biotech closes $160M round to start gene therapy trial
Frontera Therapeutics, a China and US biotech, has closed a $160 million Series B and received regulatory clearance to test its first gene therapy stateside …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.